This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Today’s guest post comes from Karina Castagna, SVP of Access and Adherence at OptimizeRx. Karina discusses the challenges health care providers and patients face in their quest to secure prior authorizations from payers. She argues that manufacturers adopt an electronic health record-based solution to facilitate access to therapies, from the point of prescription through the point of dispensing at the pharmacy.
Mitral valve regurgitation is a common kind of heart disease in the United States. Not only does it impact many people today, but its prevalence is expected to double by 2030.
There are two means of gaining insight into the agency’s thinking about regulatory issues related to promotional communications by pharmaceutical companies; one is through the issuance of guidance documents, the other is through enforcement. But when it comes to enforcement things have changed greatly over the years. In 1998, there were 156 letters issued in a single year.
This chart shows the companies which have received the most New Patient Population exclusivities in the past five years. New Patient Populations are one of the categories for which the…. The post Pharmaceutical companies with the most ‘New Patient Population’ drugs appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Watch out! Plan sponsors are getting even bolder in their attempts to grab financial support intended for patients. The latest scam is called a specialty carve-out. Here’s the game: A commercial plan eliminates coverage for all specialty drugs. Beneficiaries are then shunted over to a charitable foundation, because they are now disguised as uninsured—at least for specialty drugs.
Complement 3 glomerulopathy (C3G) is a rare type of kidney disease, estimated to impact just 1 to 2 million people worldwide. C3G is a genetically inherited disorder that impacts all races and genders equally, and the average patient is diagnosed between the ages of 21 and 26.
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Complement 3 glomerulopathy (C3G) is a rare type of kidney disease, estimated to impact just 1 to 2 million people worldwide. C3G is a genetically inherited disorder that impacts all races and genders equally, and the average patient is diagnosed between the ages of 21 and 26.
Molecular map reveals insights into the genetic drivers of chronic lymphocytic leukemia By Karen Zusi-Tran August 4, 2022 Breadcrumb Home News Molecular map reveals insights into the genetic drivers of chronic lymphocytic leukemia New map of chronic lymphocytic leukemia could potentially help identify new diagnostic markers, offer more accurate prognoses, and develop novel treatments.
This chart shows the drugs with the most patents in Colombia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Colombia? appeared first on DrugPatentWatch - Make Better Decisions.
Perhaps one of the most important aspects of a clinical trial is the informed consent process. Stemming from the ethical principle of Respects for Persons in 1976, the Belmont Report established informed consent parameters, a process designed to provide information to allow potential participants to make the best decision for themselves. This must occur prior to participating in the research.
Modern radiopharmaceutical companies are stacked with experienced experts who are laser-focused on correcting the missteps and misfortunes of earlier pioneers
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Gallery Program By Maria Nemchuk August 2, 2022 Breadcrumb Home Gallery Program RE:presentation (Chapter 2) by Emilio Vavarella November 22, 2023-March 20, 2024 An exhibit in the Second Floor Connector Gallery and Stanley Building Lobby. Stemming from his previous work in which his mother wove a textile out of his genetic code , now in the permanent collection of the Museum of Modern Art in Bologna, Italy, at Broad, Emilio has been working on a custom software that translates an individual’s
Annual Drug Patent Expirations for HYSINGLA+ER Hysingla Er is a drug marketed by Purdue Pharma Lp and is included in one NDA. It is available from one supplier. There are…. The post New patent expiration for Purdue Pharma drug HYSINGLA ER appeared first on DrugPatentWatch - Make Better Decisions.
The pandemic proved decentralized clinical trials (DCTs) can reduce patient burden while delivering quality data in a streamlined environment. In an effort to keep up with current technological trends, along with both site and participant interest, many sponsors are considering switching to a DCT model by building their own, purchasing, or licensing DCT technology.
Hot off the press, The State of Automated Pipetting 2022 shines a light on what's driving laboratories to automate their day-to-day liquid handling tasks. Across many application areas, researchers and lab staff are transitioning away from handheld pipettors to automated pipetting solutions. Drawing on insights gathered from professionals in biotech, pharma, CROs, and research institutions, our survey report explores the current automation adoption trends for liquid handling.
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Today’s post is for procedure geeks, especially those who litigate MDLs. Offensive non-mutual collateral estoppel prevents a defendant from relitigating an issue that it lost in earlier litigation against a different plaintiff. The issue is when offensive non-mutual collateral estoppel applies to a case that was part of an MDL. More specifically, the issue is which state’s law determines whether offensive non-mutual collateral estoppel applies in a particular case.
This chart shows the pharmaceutical companies with the most patents in Finland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Finland? appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for NUCYNTA Nucynta is a drug marketed by Collegium Pharm Inc and is included in three NDAs. It is available from one supplier. There are eight…. The post New patent expiration for Collegium Pharm drug NUCYNTA appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for NUCYNTA+ER Nucynta Er is a drug marketed by Collegium Pharm Inc and is included in one NDA. It is available from two suppliers. There are…. The post New patent expiration for Collegium Pharm drug NUCYNTA ER appeared first on DrugPatentWatch - Make Better Decisions.
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Annual Drug Patent Expirations for XERMELO Xermelo is a drug marketed by Tersera and is included in one NDA. It is available from two suppliers. There are five patents protecting…. The post New patent for Tersera drug XERMELO appeared first on DrugPatentWatch - Make Better Decisions.
This chart shows the drugs with the most patents in Japan. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Japan? appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for CAROSPIR Carospir is a drug marketed by Cmp Dev Llc and is included in one NDA. It is available from two suppliers. There are five…. The post New patent for Cmp Dev drug CAROSPIR appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for VEKLURY Veklury is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier. There are ten…. The post New patent for Gilead Sciences drug VEKLURY appeared first on DrugPatentWatch - Make Better Decisions.
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
This chart shows the drugs with the most patents in Slovenia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Slovenia? appeared first on DrugPatentWatch - Make Better Decisions.
Expiring drug patents are continuously driving innovation, as branded firms seek out new high-margin opportunities. Examining the patent expirations by year can indicate which pharmaceutical companies face the most peril…. The post Drugs facing the most patent expirations this year appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for ADDYI Addyi is a drug marketed by Sprout Pharms and is included in one NDA. It is available from one supplier. There are four patents…. The post New patent expiration for Sprout Pharms drug ADDYI appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for MACRILEN Macrilen is a drug marketed by Novo and is included in one NDA. It is available from two suppliers. There are two patents protecting…. The post New patent expiration for NOVO drug MACRILEN appeared first on DrugPatentWatch - Make Better Decisions.
This chart shows the drugs with the most patents in Cyprus. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Cyprus? appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for EVAMIST Evamist is a drug marketed by Padagis Us and is included in one NDA. It is available from one supplier. There is one patent…. The post New patent expiration for Padagis Us drug EVAMIST appeared first on DrugPatentWatch - Make Better Decisions.
MACRILEN (macimorelin acetate) Novo Patent: 6,861,409 Expiration: Aug 1, 2022 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or…. The post Drug Patent Expirations for the Week of July 31, 2022 appeared first on DrugPatentWatch - Make Better Decisions.
MACRILEN (macimorelin acetate) Novo Patent: 6,861,409 Expiration: Aug 1, 2022 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or…. The post Drug Patent Expirations for the Week of July 31, 2022 appeared first on DrugPatentWatch - Make Better Decisions.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
98 
Let's personalize your content